Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA.

3 Dec 2014

Myriad Genetics to highlight clinical data from three Prolaris studies at SUO 2014

Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.

3 Dec 2014

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects.

2 Dec 2014

CCR5 receptor plays key role in driving prostate cancer metastases

Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. In a study published online December 1st in the journal Cancer Research, researchers show that the receptor CCR5 best known for its role in HIV therapy, may also be involved in driving the spread of prostate cancer to the bone.

1 Dec 2014

Study finds striking gap in cancer survival between countries and regions

The CONCORD-2 study, published in The Lancet, reports 5-year survival estimates for 25·7 million cancer patients diagnosed with one of 10 common cancers and 75 000 children diagnosed with acute lymphoblastic leukaemia between 1995 and 2009, using individual patient data from 279 cancer registries in 67 countries.

28 Nov 2014

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Testosterone (T) therapy is routinely used in men with hypogonadism, a condition in which diminished function of the gonads occurs. Although there is no evidence that T therapy increases the risk of prostate cancer (PCa), there are still concerns and a paucity of long-term data.

25 Nov 2014

Study: Selenium compounds appear to have beneficial effect on cancer

The immune system is designed to remove things not normally found in the body. Cells undergoing change, e.g. precursors of cancer cells, are therefore normally recognised and removed by the immune system. Unfortunately, the different cancer cells contain mechanisms that block the immune system's ability to recognise them, allowing them to freely continue cancer development.

25 Nov 2014

Study shows effectiveness of VolitionRx’s NuQ test in detecting lung cancer in blood and sputum

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that data from its pilot lung cancer study will be presented at the Science for Business BioWin Day 2014, being held November 26, 2014 in Louvain-la-Neuve, Belgium.

25 Nov 2014

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.

24 Nov 2014

20th annual edition of NCCN Guidelines for Prostate Cancer published

The National Comprehensive Cancer Network has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer—one of the eight original NCCN Guidelines published in November 1996.

23 Nov 2014

Researchers uncover 'monstrous' hidden nature of molecule involved in prostate cancer

Researchers who have uncovered the 'monstrous' hidden nature of a molecule involved in prostate cancer say the findings could herald a new form of personalised medicine for patients, with doctors able to use the same molecular target for diagnosis and treatment.

20 Nov 2014

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).

18 Nov 2014

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy - and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal European Urology, points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients.

17 Nov 2014

New anti-cancer drug may protect normal cells against radiation

Although radiation treatments have become much more refined in recent years, it remains a challenge to both sufficiently dose the tumor while sparing the surrounding tissue.

14 Nov 2014

Researchers develop genetic test to predict prostate cancer recurrence

Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy.

13 Nov 2014

New DNA-based test could better predict treatment outcomes for prostate cancer patients

Researchers at The Ontario Institute for Cancer Research and University Health Network, have identified a new DNA-based test that could be used to better predict how prostate cancer patients will respond to treatment and to prevent relapse.

13 Nov 2014

CMS to cover low-dose CT screening for lung cancer

The Centers for Medicare and Medicaid Services today recognized the importance of lung cancer screening, announcing today that it will cover low-dose computed tomography (CT) screening, or "CAT" scans , for high-risk current and former smokers. The decision validates Mount Sinai's longstanding commitment to providing access to this essential screening tool.

12 Nov 2014

Breakthrough study shows novel molecular imaging drug to detect early prostate cancer

A novel study demonstrates the potential of a novel molecular imaging drug to detect and visualize early prostate cancer in soft tissue, lymph nodes and bone. The research, published in the November issue of the Journal of Nuclear Medicine, compares the biodistribution and tumor uptake kinetics of two Tc-99m labeled ligands, MIP-1404 and MIP-1405, used with SPECT and planar imaging.

11 Nov 2014

New treatment could halt growth of tumours in prostate cancer patients

Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer.

11 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Myriad Genetics to highlight clinical data from three Prolaris studies at SUO 2014

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

CCR5 receptor plays key role in driving prostate cancer metastases

Study finds striking gap in cancer survival between countries and regions

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Study: Selenium compounds appear to have beneficial effect on cancer

Study shows effectiveness of VolitionRx’s NuQ test in detecting lung cancer in blood and sputum

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

20th annual edition of NCCN Guidelines for Prostate Cancer published

Researchers uncover 'monstrous' hidden nature of molecule involved in prostate cancer

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

New anti-cancer drug may protect normal cells against radiation

Researchers develop genetic test to predict prostate cancer recurrence

New DNA-based test could better predict treatment outcomes for prostate cancer patients

CMS to cover low-dose CT screening for lung cancer

Breakthrough study shows novel molecular imaging drug to detect early prostate cancer

New treatment could halt growth of tumours in prostate cancer patients

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in